• Freedom
  • Innovation
  • Growth

Budget and Deficit

September 3, 2020

An Easy Way for States to Save Health Care Dollars

If state and local government employees were to substitute more biosimilars for brand name biologic drugs, governments could save millions of dollars in tight budget times.

August 26, 2020

The Taxing Ticket

In 2021 the economy will need pro-growth, not pro-government, policies to enable economic recovery. But the Biden/Harris ticket is promising the opposite.

August 20, 2020

Fact-shaming Michelle Obama's DNC Speech

In her emotion-driven speech to the virtual Democratic National Convention, Obama made several claims that are at best misleading. And if the media won’t do its job in pointing out these contradictions, others have to. 

August 11, 2020

The Real Looting Has Shifted to Washington

The looting occurring in many major cities pales in comparison to the looting Democrats will inflict on taxpayers.

July 21, 2020

Coalition Letter Regarding CARES Act Benefit Expiration

While originally intended to provide additional upport for families and businesses complying with government-mandated economic restrictions to address COVID-19, the policy of providing supplemental unemployment insurance has stifled our nation's recovery and is keeping Americans from returning to work.

July 17, 2020

Relief, Stimulus, and the Right Kind of Stimulus

Any new legislation designed to mitigate the continuing impact of the Covid-19 pandemic should contain both relief and stimulus measures, and full business expensing is an excellent candidate for the stimulus part of the package.

July 14, 2020

Joe Biden's 'Buy American or Else' Proposal

Democrats have long criticized President Trumps' economic policies, yet Joe Biden is now plagiarizing some of them—and making them worse. 

July 11, 2020

How Trump Can Get His Mojo Back

In this op/ed written for The Hill, the author offers some key points that could impact the election. 

May 30, 2020

Biosimilars Are Key in Good Health, Taxpayer Savings

Americans are the world’s top users of generics, but not of biosimilars. State and local governments should encourage a wider uptake for their own employees as an important start—and a much-needed cost savings. 

Total Records: 271